NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the receipt of a "DISCIPLINE REVIEW LETTER" from the US Food and Drug Administration requesting "MINOR" changes to the submitted label for NRx’s Preservative-Free Ketamine product. The letter requests that the Company submits sample labeling with the proposed proprietary product name currently under review in advance of the November 10, 2026, Abbreviated New Drug Application GDUFA goal date.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.